Shire plc, of Dublin, reported that for the full year of 2015 its product sales, excluding Intuniv, were up 10 percent, with growth driven by Vyvanse (lisdexamfetamine dimesylate) for the treatment of attention deficit hyperactivity disorder in adults (up 19 percent to $1.722 billion), Cinryze (up 23 percent to $618 million), and Lialda/Mezavant (up 8 percent to $684 million). Total product sales generated $6.1 billion (2014: $5.83 billion); total revenues were up 7 percent to $6.4 billion (2014: $6,022 million).